Zenas BioPharma, Inc. (ZBIO)
(Delayed Data from NSDQ)
$14.80 USD
-0.90 (-5.73%)
Updated Aug 7, 2025 04:00 PM ET
After-Market: $14.82 +0.02 (0.14%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ZBIO 14.80 -0.90(-5.73%)
Will ZBIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ZBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ZBIO
Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS
Sixteen new option listings on July 23rd
ZBIO Crosses Above Key Moving Average Level
Zenas BioPharma assumed with an Overweight at Morgan Stanley
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ZBIO Stock News